Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: A retrospective cohort study of children, adolescents and young adults using the general practice research database

Drug Safety

Volumn 32, Issue 11, 2009, Pages 1089-1096

  McCarthy, Suzanne ^a   Cranswick, Noel ^b   Potts, Laura ^c   Taylor, Eric ^c   Wong, Ian C K ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; DEXAMPHETAMINE; METHYLPHENIDATE;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CAUSE OF DEATH; CHILD; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DRUG OVERDOSE; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STANDARDIZED MORTALITY RATIO; SUDDEN DEATH; SUICIDAL IDEATION; SUICIDE;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DATABASES, FACTUAL; DEATH, SUDDEN; DEXTROAMPHETAMINE; FEMALE; GREAT BRITAIN; HUMANS; MALE; METHYLPHENIDATE; PROPYLAMINES; RETROSPECTIVE STUDIES; RISK FACTORS; SUICIDE; YOUNG ADULT;

EID: 70349976442     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11317630-000000000-00000     Document Type: Article

References (38)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
2. NICE. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults CG72. London: National Institute for Health and Clinical Excellence, 2008
3. Biederman J, Spencer T, Wilens T. Evidence-based pharmaco-therapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol 2004; 7: 77-97
4. Atomoxetine SPC. Summary of product characteristics. Strattera® Eli Lilly and Company Limited. Electronic medicines compendium [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2007 Jul 27]
5. Wilens TE, Biederman J, Lerner M, and the Concerta® Study Group. Effects of once-daily osmotic-release methyl-phenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study. J Clin Psychopharmacol 2004; 24: 36-41
6. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006; 59: 829-835
7. Findling RL, Short EJ, Manos MJ. Short-term cardiovas-cular effects of methylphenidate and adderall. J Am Acad Child Adolesc Psychiatry 2001; 40: 525-529
8. Wilens T, McBurnett K, Pelham W, et al. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2005; 44: 1015-1023
9. Wilens T, Hammerness P, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatry 2005; 66: 253-259
10. Weisler R, Biederman J, Spencer T, et al. Long-term cardio-vascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectrums 2005; 10: 35-43 (Pubitemid 43010496)
11. Wernicke JF, Faries D, Girod D. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26: 729-740
12. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006; 354: 1445-1448
13. Food and Drug Administration Center for Drug Evalua-tion and Research. Review of AERS data for marketed safety experience during stimulant therapy: death sudden death cardiovascular SAEs (including stroke) [online]. Available from URL http://www.fda.gov/ohrms/dockets/ ac/06/briefing/2006-4202B1-05-FDA- Tab05.pdf [Accessed 2006 Oct 3]
14. Food and Drug Administration news. FDA directs ADHD drug manufacturers to notify patients about cardiovascular adverse events and psychiatric adverse events [online]. Available from URL http://www.fda.gov/bbs/topics/NEWS/2007/ NEW01568.html [Accessed 2007 May 5].
15. Food and Drug Administration news: ADRQ and FDA to collaborate in largest study ever of possible heart risks with ADHD medications [online]. Available from URL http://www.fda.gov/bbs/topics/NEWS/2007/NEW01700.html [Accessed 2007 Nov 6].
16. Wong IC, Murray ML. The potential of UK clinical data-bases in enhancing paediatric medication research. Br J Clin Pharmacol 2005; 59: 750-755
17. Walley T, Mantgani A. The UK General Practice Research database. Lancet 1997; 350: 1097-1099
18. Smeeth L, Cook C, Fombonne E, et al. MMR vaccination and pervasive developmental disorders: a case-control study. Lancet 2004; 364: 963-969
19. McCarthy S, Asherson P, Coghill D, et al. ADHD: treat-ment discontinuation in adolescents and young adults. Br J Psychiatry 2009; 194: 273-277
20. Thompson PL, Gilbert RE, Long PF, et al. Effect of anti-biotics for otitis media on mastoiditis in children: a retrospective cohort study using the UK General Practice Research Database. Pediatrics 2009; 123: 424-430
21. Murray ML, de Vries CS, Wong ICK. A drug utilisation study of antidepressants in children and adolescents using the General Practice Research Database. Arch Dis Child 2004; 89: 1098-1102
22. Ackers R, Murray ML, Besag FMC, et al. Prioritising chil-dren?s medicines for research: a pharmacoepidemiological study on antiepileptic drugs. Br J Clin Pharmacol 2007; 63: 689-697
23. Rani F, Murray M, Byrne P, et al. Epidemiology of anti-psychotic prescribing to children and adolescents in UK primary care. Pediatrics 2008; 121: 1002-1009
24. Clark TG, Bradburn MJ, Love SB, et al. Survival analysis, part I: basic concepts and first analyses. Br J Cancer 2003; 89: 232-238
25. Wong ICK, Ackers R, Besag F, et al. Mortality following antiepileptic drug use in paediatrics (MAP). MHRA commissioned Pharmacoepidemiology Research final report. London: Medicines and Healthcare product Regulatory Agency, 2009
26. Roberts WC. Sudden cardiac death: definitions and causes. Am J Cardiol 1986; 57: 1410-1413
27. Wren C, O?Sullivan JJ, Wright C. Sudden death in children and adolescents. Heart 2000; 83: 410-413
28. Breslow NE, Day NE. Statistical methods in cancer research. Vol.II: the design and analysis of cohort studies. Lyon: International Agency for Research on Cancer, 1987
29. Berger S, Kugler JD, Thomas JA, et al. Sudden cardiac death in children and adolescents: introduction and overview. Pediatr Clin North Am 2004; 51: 1201-1209
30. Medicines and Healthcare products Regulatory Agency. Yellow Card System. Drug analysis prints [online]. Available from URL http://www.mhra.gov.uk/home/ idcplg?Idc Service=SS-GET-PAGE&nodeId=742 [Accessed 2007 Sep 6].
31. Vetter V, Elia J, Erickson C, et al. Cardiovascular moni-toring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008; 117: 2407-2423
32. Perrin J, Friedman R, Knilans T, et al. Cardiovascular monitoring and stimulant drugs for attention-deficit/ hyperactivity disorder. Pediatrics 2008; 112: 451-453
33. James A, Lai F, Dahl C. Attention deficit hyperactivity disorder and suicide: a review of possible associations. Acta Psychiatr Scand 2004; 110: 408-415
34. Cox D, Merkel L, Penberthy J, et al. Impact of methyl-phenidate delivery profiles on driving performance of adolescents with attention-deficit/ hyperactivity disorder: a pilot study. J Am Acad Child Adolesc Psychiatr 2004; 43: 269-275
35. Barkley RA, Murphy KR, DuPaul GI, et al. Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsychol Soc 2002; 8: 655-672
36. Biederman J, Fried R, Monuteaux M, et al. A laboratory driving simulation for assessment of driving behaviour in adults with ADHD: a controlled study. Ann Gen Psychiatr 2007; 6: 4
37. Wilens TE, Biederman J, Mick E, et al. Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorder. J Nerv Ment Dis 1997; 185: 475-482
38. Wilens T, Faraone S, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003; 111: 179-185